Puma Biotechnology Inc. sell JosefS
Start price
21.08.19
/
50%
€9.73
Target price
04.11.21
€5.00
Performance (%)
-57.83%
End price
05.11.21
€4.10
Summary
This prediction ended on 05.11.21 with a price of €4.10. JosefS correctly predicted massive losses of -57.83% for Puma Biotechnology Inc.. JosefS has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Puma Biotechnology Inc. | -6.159% | -6.159% | 78.968% | -47.497% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
Comments by JosefS for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Die letzten Zahlen waren zwar besser als erwartet aber die Pipeline sieht immer noch nicht sehr vielversprechend aus.
In the thread Trading Puma Biotechnology Inc.
Die von JosefS gewählte maximale Laufzeit wurde überschritten